Affiliation:
1. Department of Medical OncologyState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat‐Sen University Cancer Center510060GuangzhouGuangdongChina
2. Department of Clinical ResearchState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat‐Sen University Cancer Center510060GuangzhouGuangdongChina
Funder
National Key R&D Program of China
Science and Technology Planning Project of Guangdong Province
Guangzhou Science and Technology Program key projects
Young Scientists Fund
National Natural Science Foundation of China
Pearl River S and T Nova Program of Guangzhou
Young Teacher Foundation of Sun Yat-sen University
Subject
Molecular Medicine,Medicine (miscellaneous)
Reference35 articles.
1. Pan‐Asian adapted clinical practice guidelines for the management of patients with metastatic non‐small‐cell lung cancer: a CSCO‐ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS;Wu YL;Ann Oncol,2019
2. Osimertinib or platinum‐pemetrexed in EGFR T790M‐positive lung cancer;Mok TS;N Engl J Med,2017
3. AZD9291 in EGFR inhibitor‐resistant non‐small‐cell lung cancer;Janne PA;N Engl J Med,2015
4. Osimertinib for pretreated EGFR Thr790Met‐positive advanced non‐small‐cell lung cancer (AURA2): a multicentre, open‐label, single‐arm, phase 2 study;Goss G;Lancet Oncol,2016
5. Heterogeneity underlies the emergence of EGFRT790 wild‐type clones following treatment of T790M‐positive cancers with a third‐generation EGFR inhibitor;Piotrowska Z;Cancer Discov,2015
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献